Scholarlink

<p>Non-small cell lung cancer (NSCLC) remains a leading cause of global mortality, necessitating novel therapies. This study investigated the therapeutic role of natural killer cell-derived exosomes (NK-Exo), whose antitumor mechanisms are incompletely understood. Exosomes were isolated from interleukin (IL)-2-independent NK-92MI cells via differential ultracentrifugation and characterized by nanoparticle tracking, electron microscopy, and western blotting. They exhibited cup-shaped morphology (50–150&#xa0;nm), expressed CD81/TSG101, and demonstrated selective cytotoxicity against tumor cells (A549, A375) but not nontumor cells (293&#xa0;T) in vitro; this effect was corroborated in patient-derived lung organoids. Small RNA sequencing revealed miR-140-3p as highly enriched in NK-Exo, and its expression correlated with improved survival in patients with NSCLC. Functional validation showed that overexpressing miR-140-3p enhanced NK-Exo cytotoxicity and directly inhibited cancer cell migration and invasion, whereas inhibiting miR-140-3p promoted tumor growth. Mechanistically, miR-140-3p directly targeted xylosyltransferase 1 (XYLT1), as confirmed by dual-luciferase assay, leading to reduced levels of heparan sulfate proteoglycan 2 (HSPG2). Knockdown of XYLT1 phenocopied the tumor-suppressive effects of miR-140-3p, while supplementation with heparan sulfate reversed them. In a Lewis lung carcinoma mouse model, intratumoral delivery of NK-Exo, miR-140-3p mimic, or XYLT1 Small interfering RNA (siRNA) significantly inhibited tumor growth and alleviated splenomegaly. In conclusion, NK-Exo deliver miR-140-3p to suppress tumors via the novel miR-140-3p/XYLT1/HSPG2 axis, presenting a promising therapeutic strategy for cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

NK-cell-derived exosomes exert antitumor potency via miR-140/XYLT1/HSPG2 axis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月11日

查看全文
  • Dingru Li,
  • Zerui Chen,
  • Herong Liang,
  • Qiang Li,
  • Xiaofan Mao,
  • Beiying Zhang,
  • Weiquan Gu,
  • Ye Xiao,
  • Xing-dong Xiong,
  • Dan Zhou,
  • Yuhua Deng,
  • Mengyun Cai

摘要

Non-small cell lung cancer (NSCLC) remains a leading cause of global mortality, necessitating novel therapies. This study investigated the therapeutic role of natural killer cell-derived exosomes (NK-Exo), whose antitumor mechanisms are incompletely understood. Exosomes were isolated from interleukin (IL)-2-independent NK-92MI cells via differential ultracentrifugation and characterized by nanoparticle tracking, electron microscopy, and western blotting. They exhibited cup-shaped morphology (50–150 nm), expressed CD81/TSG101, and demonstrated selective cytotoxicity against tumor cells (A549, A375) but not nontumor cells (293 T) in vitro; this effect was corroborated in patient-derived lung organoids. Small RNA sequencing revealed miR-140-3p as highly enriched in NK-Exo, and its expression correlated with improved survival in patients with NSCLC. Functional validation showed that overexpressing miR-140-3p enhanced NK-Exo cytotoxicity and directly inhibited cancer cell migration and invasion, whereas inhibiting miR-140-3p promoted tumor growth. Mechanistically, miR-140-3p directly targeted xylosyltransferase 1 (XYLT1), as confirmed by dual-luciferase assay, leading to reduced levels of heparan sulfate proteoglycan 2 (HSPG2). Knockdown of XYLT1 phenocopied the tumor-suppressive effects of miR-140-3p, while supplementation with heparan sulfate reversed them. In a Lewis lung carcinoma mouse model, intratumoral delivery of NK-Exo, miR-140-3p mimic, or XYLT1 Small interfering RNA (siRNA) significantly inhibited tumor growth and alleviated splenomegaly. In conclusion, NK-Exo deliver miR-140-3p to suppress tumors via the novel miR-140-3p/XYLT1/HSPG2 axis, presenting a promising therapeutic strategy for cancer.